Basel Medical Group (NASDAQ:BMGL - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Sunday.
Basel Medical Group Stock Down 4.1%
BMGL traded down $0.21 during midday trading on Friday, hitting $4.88. 4,446,582 shares of the company's stock traded hands, compared to its average volume of 4,823,242. Basel Medical Group has a one year low of $0.91 and a one year high of $9.40.
Basel Medical Group Company Profile
(
Get Free Report)
OUR MISSION Basel Medical transcends the role of a conventional healthcare provider. We strive for excellence in medical services and aim to serve as a beacon of hope for patients across Singapore and Southeast Asia. Our mission encompasses the four following commitments: Patient–Centered Care. We prioritize our patient's wellbeing above all else.
Further Reading
Before you consider Basel Medical Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Basel Medical Group wasn't on the list.
While Basel Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
